Trial site
Texas Retina Associates
Dallas, Texas 75231, United StatesNot linked to an institution yet
- 12running trials
- 14closed trials
The trials here
What the 26 trials at this site are about, from their registry records.
- Phase
- Phase 29 trials
- Phase 39 trials
- Phase 1/23 trials
- Phase 2/33 trials
- Phase 11 trial
- Status
- Completed11 trials
- Active, not recruiting7 trials
- Recruiting5 trials
- Terminated3 trials
- Lead sponsor
- Aura Biosciences3 trials
- Hoffmann-La Roche3 trials
- Apellis Pharmaceuticals, Inc.2 trials
- Aviceda Therapeutics, Inc.2 trials
- EyePoint Pharmaceuticals, Inc.2 trials
- and 13 more
Running trials
Recruiting
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
NCT07440225· Phase 2/3· EyeBiotech Ltd.· Source
Contact: Study Coordinator
Active, not recruiting
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07449936· Phase 3· EyePoint Pharmaceuticals, Inc.· Source
Recruiting
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
NCT07215390· Phase 2· Apellis Pharmaceuticals, Inc.· Source
Recruiting
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
NCT06962839· Phase 2· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Active, not recruiting
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
NCT06495918· Phase 3· Ocular Therapeutix, Inc.· Source
Recruiting
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
NCT06541704· Phase 3· Regeneron Pharmaceuticals· Source
Contact: Clinical Trials Administrator
Active, not recruiting
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
NCT06668064· Phase 3· EyePoint Pharmaceuticals, Inc.· Source
Recruiting
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT06635148· Phase 2/3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
NCT06510816· Phase 3· Annexon, Inc.· Source
Active, not recruiting
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
NCT06007690· Phase 3· Aura Biosciences· Source
Active, not recruiting
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT05769153· Phase 1/2· Alcon Research· Source
Active, not recruiting
A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma
NCT03941379· Aura Biosciences· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Terminated
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT06961370· Phase 1· Hoffmann-La Roche· Source
Completed
NT-101 Topical Ophthalmic Solution in Patients With Wet AMD
NCT06704009· Phase 1/2· NexThera Co., Ltd.· Source
Terminated
A Phase 2 Study of Intravitreal AVD-104 in Diabetic Macular Edema
NCT06181227· Phase 2· Aviceda Therapeutics, Inc.· Source
Completed
A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
NCT05839041· Phase 2· Aviceda Therapeutics, Inc.· Source
Completed
A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT05811351· Phase 2· Janssen Research & Development, LLC· Source
Completed
A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema
NCT05642312· Phase 3· Hoffmann-La Roche· Source
Completed
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
NCT06850922· Phase 1/2· Genentech, Inc.· Source
Completed
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)
NCT05066997· Phase 2/3· Oculis· Source
Completed
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
NCT04777201· Phase 3· Hoffmann-La Roche· Source
Completed
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
NCT04770545· Phase 3· Apellis Pharmaceuticals, Inc.· Source
Completed
RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)
NCT04832724· Phase 2· AbbVie· Source
Completed
Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
NCT04417530· Phase 2· Aura Biosciences· Source
Completed
A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema
NCT04527107· Phase 2· Oxurion· Source
Terminated
EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
NCT04437368· Phase 2· Gyroscope Therapeutics Limited· Source
Report an error